Cassava Sciences, Inc. (NASDAQ: SAVA) Securities Fraud Class Action

Cassava Sciences, Inc. (NASDAQ: SAVA) Securities Fraud Class Action

CompanyCassava Sciences, Inc.
CourtUnited States District Court for the Western District of Texas
Case Number24-cv-01525
JudgeHonorable David A. Ezra
Class PeriodOctober 13, 2023 through March 25, 2025
Security TypeSecurities

Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Cassava Sciences Inc. (“Cassava”) (NASDAQ: SAVA) securities between October 13, 2023 and March 25, 2025, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that: (1) Cassava’s drug, simufilam, was not capable of abating the progression of Alzheimer’s Disease, even in mild to moderate cases; and (2) as a result, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Current Status of Case:
On November 6, 2025 and November 7, 2025, Defendants filed Motions to Dismiss the Amended Complaint. The Motions have been fully briefed and are pending decision before the Court. This action is ongoing.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected]. If you would like additional information about the suit, please click on the link “Submit Your Information” above and fill out the form as promptly as possible.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. 

Complete this form with your transactions in Cassava Sciences, Inc. securities between October 13, 2023 through March 25, 2025.

Click Here to Print PDF of this Form

    Submit Your Information
    SUBMIT YOUR INFORMATION
    * Denotes required field
    Phone Country code
    Purchase Information
    Sales Information
    Did you purchase shares of Cassava Sciences, Inc. (2024) prior to the Class Period?
    Are you a current or former employee of Cassava Sciences, Inc. (2024)?
    The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. READ MORE
    I agree to the KTMC disclaimer
    I would like to receive new case alerts by email
    Scroll to Top